Vimarsana
Biggest News Aggregation in the World

Page 27 - General Internal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from General Internal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In General Internal Today - Breaking & Trending Today

Resident Thriving Model Defined In New Study - Vimarsana News

Resident Thriving Model Defined In New Study

A concept of Aristotle, eudaimonia is when a “flourishing life incorporates both a subjective feeling of satisfaction as well as a value-oriented purpose” says

Source: yale.edu
Out-of-Pocket Costs for Epinephrine Auto-Injectors Examined - Vimarsana News

Out-of-Pocket Costs for Epinephrine Auto-Injectors Examined

Cost-sharing still substantial for some using nonbranded auto-injectors, such as those enrolled in high-deductible health plans.

Source: empr.com
Out-of-Pocket Costs for Epinephrine Auto-Injectors Examined - Vimarsana News

Out-of-Pocket Costs for Epinephrine Auto-Injectors Examined

FRIDAY, July 22, 2022 (HealthDay News) -- Out-of-pocket spending for epinephrine auto-injectors decreased among privately insured patients in 2017, coinciding with availability of lower-priced nonbranded products, according to a report published online July 11 in the Journal of General Internal Medicine. Kao-Ping Chua, M.D., Ph.D., from University of Michigan in Ann Arbor, and Rena M.

Hawaii study on private lab's profits from PCR testing raises questions about US health care spending - State of Reform - Vimarsana News

Hawaii study on private lab's profits from PCR testing raises questions about US health care spending - State of Reform

The study estimated profits from PCR testing to be at least $10 per test, although the actual amount could be much higher.

Availability of lower-priced epinephrine auto-injectors did not solve the affordability problem for all patients with severe allergies - Vimarsana News

Availability of lower-priced epinephrine auto-injectors did not solve the affordability problem for all patients with severe allergies

People with severe allergies now have more choices for which epinephrine auto-injector to carry in case they suffer a life-threatening attack, and most pay less for it than they did when the EpiPen was the primary option, a new study shows.